Bruce C. Trapnell, MS, MD
- Director, Translational Pulmonary Science Center
- Attending Physician, Pulmonologist - Research, Adult Clinical, Division of Pulmonary Medicine
- Professor, UC Department of Pediatrics
- bruce.trapnell@cchmc.org
- Board Certified
About
Biography
Dr. Trapnell received his medical degree from the University of Maryland in 1985 and medical residency training at The Ohio State University Hospitals. He completed a fellowship in pulmonary medicine and then served as attending physician and senior attending physician at the Clinical Center of the National Institutes of Health. Subsequently, he served as vice president and director of the Division of Pulmonary and Virology Studies at Genetic Therapy, Incorporated, a subsidiary of Novartis.
In 1997, Dr. Trapnell joined Cincinnati Children’s Hospital Medical Center and is now a professor of Medicine and Pediatrics at the UC College of Medicine. At Cincinnati Children's, he directed Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center for more than a decade and participated in numerous clinical trials as principal investigator including studies leading to FDA-approval of Creon® and Pancreaze®. He established and directs the Rare Lung Diseases Clinical Research Consortium (RLDC) in which a study led by Frank McCormack resulted in FDA approval of Sirolimus® as therapy of Lymphangioleiomyomatosis.
Dr. Trapnell’s research group established that GM-CSF autoantibodies caused the rare lung disease autoimmune pulmonary alveolar proteinosis and established clinical laboratory tests for its diagnosis and identified hereditary pulmonary alveolar proteinosis as a new genetic disease caused by mutations in CSF2RA and CSF2RB. His research group developed a novel type of cell transplantation, pulmonary macrophage transplantation, and is currently translating it for testing as therapy in patients with the disease. The group also contributed to the identification, characterization, and methods for diagnosis of indium-related lung disease.
An ardent patient advocate, Dr. Trapnell has worked with patient foundations for cystic fibrosis (CF), alpha-1-antitrypsin deficiency, pulmonary alveolar proteinosis, lymphangioleiomyomatosis, and childhood interstitial lung diseases. He has served as past scientific director for the Alpha-1 Foundation and as co-founder and current scientific director of the Pulmonary Alveolar Proteinosis Foundation. Since coming to Cincinnati, he has provided training in basic, clinical, and translational research at pre- and post-doctoral levels.
BS: Biochemistry, University of Maryland, College Park, MD, 1978.
MS: Genetics, The George Washington University, Washington, DC, 1981.
MD: University of Maryland School of Medicine, Baltimore, MD, 1984.
Residency: Internal Medicine, The Ohio State University Hospitals, Columbus, OH, 1987.
Fellowship: Pulmonary Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, 1989.
Certification: Diplomat in Internal Medicine, American Board of Internal Medicine, 1987; Diplomat, National Board of Medical Examiners, 1987; Diplomat in Pulmonary Medicine, American Board of Internal Medicine, 2000.
Interests
Research on rare lung diseases including pulmonary alveolar proteinosis; cystic fibrosis; alpha-1 antitrypsin deficiency; lymphangioleiomyomatosis
Services and Specialties
Interests
Alveolar macrophage function; molecular techniques using gene knockout, transgenic and conditional gene expression mouse models and non-human primates, in vitro and in vivo viral gene transfer, and bone marrow transplantation
Publications
MRI and Blood-based Biomarkers Are Associated With Surgery in Children and Adults With Ileal Crohn's Disease. Inflammatory Bowel Diseases. 2024; 30:2181-2190.
European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2024; 64:2400725.
Inhaled molgramostim therapy for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP): a plain language summary of the IMPALA trial. Hospital practice (1995). 2024; 52:47-63.
Protocol to develop human alveolar macrophage-like cells from mononuclear cells or purified monocytes for use in respiratory biology research. Star Protocols. 2024; 5:103061.
A toxicology study of Csf2ra complementation and pulmonary macrophage transplantation therapy of hereditary PAP in mice. Molecular Therapy-Methods & Clinical Development. 2024; 32:101213.
Disseminated nocardiosis and anti-GM-CSF antibodies. European Journal of Clinical Microbiology and Infectious Diseases: an international journal on pathogenesis, diagnosis, epidemiology, therapy, and prevention of infectious diseases. 2024; 43:1003-1007.
MRI AND BLOOD-BASED BIOMARKERS ASSOCIATED WITH SURGICAL MANAGEMENT IN CHILDREN AND ADULTS WITH SMALL BOWEL CROHN'S DISEASE. Gastroenterology. 2024; 166:s19-s20.
MRI AND BLOOD-BASED BIOMARKERS ASSOCIATED WITH SURGICAL MANAGEMENT IN CHILDREN AND ADULTS WITH SMALL BOWEL CROHN'S DISEASE. Inflammatory Bowel Diseases. 2024; 30:s14-s15.
Human inherited CCR2 deficiency underlies progressive polycystic lung disease. Cell. 2024; 187:390-408.e23.
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2024; 63:2301233.
From the Blog
Doctors Find Drug for Lethal Lung Disease After Decades of Trying
Bruce C. Trapnell, MS, MD9/7/2020
Statins Effective in Treating Pulmonary Alveolar Proteinosis
Bruce C. Trapnell, MS, MD7/1/2019
Macrophage Transplantation Could Take Familial PAP Off the Map
Bruce C. Trapnell, MS, MD6/28/2019
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey